Bothell-based biotech company Seagen found success with one of its breast cancer therapies on Wednesday. A combination of the treatment, named Tuksya, met the goal of its late-stage study and shows promise for the company’s future.
Tuksya is designed to prolong the lives of breast cancer patients without increasing symptoms or aggravating the disease. The drug is designed to target HER2 positive, a strain of breast cancer responsible for nearly one fifth of breast cancer cases in the United States.
Earlier this year, Pfizer began the process of acquiring Seagen and its targeted therapies for $43 billion.